Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 17:03:00 EET | Press release
BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointe
Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 17:00:00 EET | Press release
Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftBank’s strategy for a Ubiquitous Network. The majority of Sceye’s initial fleet will provide mobile broadband throughout Japan, while a subset will also establish a Free Space Optical (FSO) network in the stratosphere. These deploym
SharkNinja Brings Its All-Star Neighbors and Fans Home for the Holidays3.11.2026 17:00:00 EET | Press release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today unveiled the final spot in its first-ever SharkNinja holiday campaign, starring global brand ambassadors David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka. The campaign, “There’s No Home Like a SharkNinja Home,” puts the ambassadors’ own fandom and love of Shark and Ninja products at the center of a holiday house-sitting assignment that gets a little out of hand and invites fans along for the fun. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103325477/en/ David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka celebrate a shared love and fandom of Shark and Ninja products in SharkNinja’s first-ever holiday campaign, “There’s No Home Like a SharkNinja Home” Created by SharkNinja’s in-house Creative Labs team and produced by Studio 99, the holiday campaign builds on SharkNinja’s Neighbors series, which debuted in 2025 with Beckham
Andersen Consulting Enhances Transformation Capabilities with Bakia Consulting3.11.2026 16:30:00 EET | Press release
Andersen Consulting advances its business transformation capabilities through a Collaboration Agreement with Bakia Consulting, a firm specializing in finance function transformation. Headquartered in Paris with capabilities in Singapore and Hong Kong, Bakia Consulting has helped large corporations and financial institutions redesign their finance functions, addressing operating models, organizational structures, processes, and digital systems. The firm combines project management and change management, working alongside clients to develop solutions and sustain change. Bakia Consulting also advises on financial and non-financial management models, process optimization, and digital tools. “Finance functions are being asked to deliver better insight, operate more efficiently, and adapt to changing business needs, often at the same time,” said Romain Dubuisson, partner at Bakia Consulting. “We work closely with clients to develop solutions that reflect their operational realities, combinin
Organigram to Acquire Aurora and Establish a Global Cannabis Leader3.11.2026 16:16:00 EET | Press release
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”). The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (“Curaleaf”) of its intention to launch a hostile takeover bid for Aurora (the “Unaffected Price”), and a 21% premium relative to the current bid value of the Curaleaf hostile offer3 (the “Hostile Bid”) as most recently amended on October 6, 2026, which was unanimousl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom